Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, today announced that J-Plasma™ is performing well in both laparoscopic and open surgeries. In multiple patient procedures there was a decrease in smoke, less charring and overall excellent tissue response when compared to current electrosurgery devices. Jeff Rencher, Vice President of Sales and Marketing of Surgical Products stated, “The positive results achieved by J-Plasma™ met all expectations as we prepare to embark on an aggressive marketing program for the product.” He added, “We will continue to introduce J-Plasma™ in a limited format over the next two weeks; however, with the early success of the product in human cases and the continued success and extensive use in live veterinarian cases, we will be moving into expanded markets during the current quarter. Gynecology and Plastic Surgery will continue to be the main focus for J-Plasma™. Additionally, we expect to be performing ENT and General Surgery procedures as the technology establishes itself as a viable alternative to traditional and competitive devices.” In unrelated news, the Company reported that it’s previously announced anticipated developmental and manufacturing agreement with a large multi-national medical device company remains in the due-diligence and negotiation stage. Cautionary Note on Forward-Looking Statements Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2011. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemed.com.